Third Quarter and nine Months Results 2010

Third Quarter and nine Months Results 2010

Revenue for the third quarter declined by 2 percent at constant exchange
rates (CER) to $7,898 million.

-Strong double-digit sales growth at CER for Crestor, Symbicort and
Seroquel XR.

-Revenue in markets outside the US increased by 7 percent at CER,
including a 14 percent increase in Emerging Markets.

-As expected, revenue in the US was affected by generic competition for
Arimidex, Pulmicort Respules and Toprol-XL, as well as the absence of
H1N1 pandemic influenza vaccine revenue that benefited the third quarter
2009.  US revenue was down 13 percent at CER in the third quarter.

Core operating profit in the third quarter was down 10 percent at CER to
$3,231 million.

-With the impact from lower revenue being largely mitigated by operating
efficiencies and higher other income, the decline in Core operating
profit is chiefly the result of a net $285 million adverse movement in
gross margin - an intangible asset impairment charge this quarter set
against a favourable provision release last year.

Core EPS in the third quarter was down 10 percent at CER to $1.50.

Reported EPS in the third quarter was down 26 percent at CER to $1.08.
  

-Restructuring costs and legal provisions were higher compared with the
third quarter last year, with the largest impact arising from legal
provisions totalling $473 million in the third quarter 2010 which are
related to ongoing product liability litigation for Seroquel (see Note
5).   

Net cash distributions to shareholders for the nine months increased to
$4,658 million through dividend payments of $3,361 million and net share
repurchases of $1,297 million.

Core EPS target for the full year narrowed to the range of $6.50 to
$6.65.

(Table included in attached PDF)

David Brennan, Chief Executive Officer, said:  “We remain firmly on
track to achieve our full year financial targets. The third quarter
performance featured double-digit revenue growth in Emerging Markets. 
Revenue also increased in Western Europe and Established Rest of World. 
As expected, the impact of generic competition on several products and
the absence of pandemic flu vaccine revenue led to a challenging quarter
in the US.”

Media Enquiries:            Neil McCrae (London)            (020) 7604
8236
                            Sarah Lindgreen (London)        (020) 7604
8033
                            Tony Jewell (Wilmington)        (302) 885
4594
                            Ann-Leena Mikiver (Södertälje)  (8) 553 260
20
                                                             
Analyst/Investor Enquiries  Karl Hård (London)              (020) 7604
8123
                            Jonathan Hunt (London)          (020) 7604
8122
                            Clive Morris (London)           (020) 7604
8124
                            Ed Seage/Jörgen Winroth (US)    (302) 886
4065/(212) 579 0506